Latest Health News

New Zealand King Salmon reported an FY25 net loss driven by a shortened reporting period and biological challenges, while advancing its Blue Endeavour pilot project despite delays. The company projects a cautious recovery in FY26 with EBITDA guidance between NZD 9 million and 15 million.

New Zealand King Salmon reports a $6.3 million net loss for an eight-month FY25 period, reflecting operational challenges and a shortened reporting cycle, while outlining cautious optimism for FY26 with targeted growth investments.

Adherium Limited has reached a pivotal commercial milestone by expanding its Remote Patient Monitoring program across 110 U.S. Allergy Partners clinics, activating nearly 70% of the network and onboarding close to 700 patients in six months.

Anatara Lifesciences has completed the final tranche of its placement, issuing over 66 million shares and granting options to its lead manager, marking a key step in its capital raising strategy.

InhaleRx Limited has introduced SRX-25, an oral fixed-dose combination therapy targeting Treatment-Resistant Depression, aiming to improve patient access and adherence. The company also secured $1 million in capital to advance clinical development and plans a strategic rebrand.

Proteomics International secures a key Medicare reimbursement rate for its PromarkerD test, a predictive diagnostic for diabetic kidney disease, marking a critical step in its US commercial rollout.

Recce Pharmaceuticals has reported compelling preclinical results for its inhaled anti-infective RECCE 327, demonstrating potent activity against multidrug-resistant pneumonia bacteria in mice models.

Race Oncology has received ethics approval to launch its HARNESS-1 Phase 1a/b trial testing RC220 combined with osimertinib in EGFR-mutated non-small cell lung cancer patients, marking a key step toward addressing resistance to current therapies.

Audeara Limited has secured a $1.22 million R&D tax incentive refund for FY25, strengthening its financial position by repaying debt and retaining non-dilutive funding to fuel ongoing product development.

Cleo Diagnostics has secured a $1.7 million R&D tax refund, strengthening its cash reserves to $5.75 million as it advances toward a pivotal US clinical trial and FDA submission for its ovarian cancer test.

Brazilian Critical Minerals Ltd has been served with a writ alleging breach of a convertible loan agreement tied to share issuance and pricing, sparking a legal dispute with a US investment firm.

K&S Corporation has issued a cautious earnings update, forecasting a significant decline in underlying profit before tax for the first half of 2025 compared to last year.